FTC clears Mylan merger with Pfizer’s Upjohn – with conditionsMylan’s $12 billion takeover of Pfizer’s Upjohn unit has been cleared by the US authorities, but on the Share XFTC clears Mylan merger with Pfizer’s Upjohn – with conditionshttps://pharmaphorum.com/news/ftc-clears-mylan-merger-with-pfizers-upjohn-with-conditions/
Coronavirus pandemic delay Mylan and Pfizer’s generics mergerMylan’s merger with Pfizer’s off-patent drug business has been delayed until later this year because of the coronavirus Share XCoronavirus pandemic delay Mylan and Pfizer’s generics mergerhttps://pharmaphorum.com/news/coronavirus-pandemic-delay-mylan-and-pfizers-generics-merger/
COVID-19 could disrupt supplies of cheap generics, analysts warnAn extended COVID-19 coronavirus outbreak could impact on supplies of generic drugs that many health systems rely on Share XCOVID-19 could disrupt supplies of cheap generics, analysts warnhttps://pharmaphorum.com/news/covid-19-could-disrupt-supplies-of-cheap-generics-moodys/
Biogen claims victory in patent dispute with Mylan over MS drug TecfideraShares in Biogen are on the rise after the company successfully defended its blockbuster multiple sclerosis drug Tecfidera Share XBiogen claims victory in patent dispute with Mylan over MS drug Tecfiderahttps://pharmaphorum.com/news/biogen-claims-victory-in-patent-dispute-with-mylan-over-ms-drug-tecfidera/
Chasing Mylan, Hikma tries again with rejected generic Advair in USUK-listed Hikma Pharma has filed a response to the FDA that it hopes will clear the way for Share XChasing Mylan, Hikma tries again with rejected generic Advair in UShttps://pharmaphorum.com/news/chasing-mylan-hikma-tries-again-with-rejected-generic-advair-in-us/
Mylan’s Lantus biosimilar held up by manufacturing issueMylan’s hopes of grabbing a slice of the big US market for insulin glargine – the active ingredient Share XMylan’s Lantus biosimilar held up by manufacturing issuehttps://pharmaphorum.com/news/mylans-lantus-biosimilar-held-up-by-manufacturing-issue/
Mylan up on OK for generic of Lilly’s $2bn cancer drug AlimtaShares in Mylan have risen after the FDA gave a tentative approval to its generic version of Eli Share XMylan up on OK for generic of Lilly’s $2bn cancer drug Alimtahttps://pharmaphorum.com/news/mylan-up-on-ok-for-generic-of-lillys-2bn-cancer-drug-alimta/
Hikma buys potential Epipen rival from troubled InsysUK-based pharma Hikma has snapped up assets from embattled Insys Therapeutics, including potential generics of Mylan’s Epipen allergic Share XHikma buys potential Epipen rival from troubled Insyshttps://pharmaphorum.com/news/hikma-buys-potential-epipen-generic-from-insys/
Pfizer confirms generic medicines merger with MylanPfizer and Mylan have announced an all-stock deal that would combine their off-patent medicines businesses, confirming speculation that Share XPfizer confirms generic medicines merger with Mylanhttps://pharmaphorum.com/news/pfizer-confirms-generic-medicines-merger-with-mylan/
